Loading...
•
Dec 31, 2021
Cogent Biosciences Q4 2021 Earnings Report
Cogent Biosciences reported financial results for Q4 2021, with ongoing clinical trials and sufficient cash to fund operations into 2024.
Key Takeaways
Cogent Biosciences announced its Q4 and full year 2021 financial results, highlighting the active enrollment in APEX, SUMMIT, and PEAK clinical trials. The company ended the year with $219.7 million in cash and cash equivalents, expected to fund operations into 2024. An R&D Investor Event is planned for April 8, 2022.
APEX, SUMMIT and PEAK bezuclastinib clinical trials are actively enrolling patients.
Initial clinical data presentation from APEX is expected in the first half of 2022.
An R&D Investor Event is planned for April 8, 2022.
Ended 2021 with $219.7 million in cash, sufficient to fund operations into 2024.
Cogent Biosciences
Cogent Biosciences
Forward Guidance
Cogent Biosciences anticipates a cash runway into 2024 and expects to present preliminary clinical data from APEX in the first half of 2022. The company is planning an R&D investor event in April 2022 and anticipates the Cogent Research Team will move into its new facility this spring. AACR poster presentations are expected to be available through the AACR conference website on schedule.
Positive Outlook
- Cash runway anticipated into 2024
- Preliminary clinical data from APEX expected in the first half of 2022
- R&D investor event planned for April 2022
- Cogent Research Team anticipated to move into new facility this spring
- AACR poster presentations expected to be available through the AACR conference website on schedule.